Drug utilization evaluation of vancomycin in teaching hospitals of Lahore

Journal of Pharmaceutical Sciences and Research

Volumn 4, Issue 2, 2012, Pages 1728-1733

  Tarar, Wasam Liaqat ^a   Farooq, Mehreen ^a   Amin, Fatima ^a   Mahmood, Khawaja Tahir ^b  

^a LAHORE COLLEGE FOR WOMEN UNIVERSITY   (Pakistan)

^b Drug Testing Laboratory   (Pakistan)

Author keywords

Cost effectiveness; Evaluation; Patient outcomes; Rational; Utilization

Indexed keywords

UNCLASSIFIED DRUG; VANCOMYCIN; VINJEC;

ADVERSE DRUG REACTION; ANTIBACTERIAL ACTIVITY; ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG FATALITY; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG INFUSION; DRUG USE; ENDOCARDITIS; GRAM POSITIVE INFECTION; HEALTH CARE PERSONNEL; HUMAN; INFORMATION PROCESSING; OUTCOME ASSESSMENT; PAKISTAN; PERITONITIS; PHARMACIST; PRESCRIPTION; PSEUDOMEMBRANOUS COLITIS; REDMAN SYNDROME; TEACHING HOSPITAL; TINNITUS;

EID: 84857326661     PISSN: None     EISSN: 09751459     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. David A. Stempel, Joyce F. Durcannin-Robbins, Edwin C. Hedblom, Roger Woolf, Linda L. Sturm, Amanda B. Stempel. Drug Utilization Evaluation Identifies Costs Associated with High Use of Beta-Adrenergic Agonists. Annal of Allergy, Asthma and Immunology 76 (2): 153-158 (1996).
2. Navarro, Robert. Drug Utilization Review Strategies. Managed Care Pharmacy Practice, published 2008, Chapter 8, pp. 215-229.
3. American Society of Health-System Pharmacists. ASHP Guidelines on Medication-Use Evaluation. Vol. 53: 1953-5 (1996).
4. Griffith RS. (1981). Introduction to vancomycin. Rev Infect Dis 3: S2004.
5. Robert C. Moellering Jr. Pharmacokinetics of vancomycin. Journal of Antimicrobial Chemotherapy. 14 (Issue suppl D): 43-52 (1984).
6. Small PM, Chambers HF. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother 34 (6): 1227-31 (1990).
7. [Gonzalez C, Rubio M, Romero-Vivas J, Gonzalez M, Picazo J. Bacteremic pneumonia due to Staphylococcus aureus: a comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms". Clin Infect Dis 29 (5): 1171-7. doi: 10.1086/313440 (1999).
8. [Rossi S. Adelaide: Australian Medicines Handbook; 2006. ISBN 0-9757919-2-3
9. Recommendations for Preventing the Spread of Vancomycin Resistance Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC) 1995 Available at: http://wonder.cdc.gov/wonder/prevguid/m0039349/m0039349.asp Retrieved on: April 22, 2011
10. Levine, D. Vancomycin: A History. Clin Infect Dis 42: S5-S12. doi: 10.1086/491709 (2006).
11. Moellering, RC Jr. Vancomycin: A 50-Year Reassessment. Clin Infect Dis 42 (Suppl 1): S3-S4. doi: 10.1086/491708 (2006).
12. Drygalski A, Curtis BR. Vancomycin-Induced Immune Thrombocytopenia. N Engl J Med 356 (9): 904. doi:10.1056/NEJMoa065066 (2007).
13. Smith, TL; Pearson, ML; Wilcox, KR; Cruz, C; Lancaster, MV; Robinson-Dunn, B; Tenover, FC; Zervos, MJ et al. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. The New England journal of medicine 340 (7): 493-501. doi: 10.1056/NEJM199902183400701 (1999).
14. McDonald, LC; Killgore, GE; Thompson, A; Owens Jr, RC; Kazakova, SV; Sambol, SP; Johnson, S; Gerding, DN. An epidemic, toxin gene-variant strain of Clostridium difficile. The New England journal of medicine 353 (23): 2433-41. doi: 10.1056/NEJMoa051590 (2005).